Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with results posted in Mar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• NIR178
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-03-01